{"id":"NCT05413369","sponsor":"Sanofi","briefTitle":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","officialTitle":"A Randomized, 24 Weeks, Active-controlled, Open-label, 2-arm Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to IDegAsp in Chinese Type 2 Diabetes Mellitus Participants Insufficiently Controlled With Oral Antidiabetic Drug(s)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-07-07","primaryCompletion":"2023-10-20","completion":"2023-10-20","firstPosted":"2022-06-10","resultsPosted":"2024-10-30","lastUpdate":"2024-10-30"},"enrollment":582,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Insulin glargine/Lixisenatide","otherNames":[]},{"type":"DRUG","name":"IDegAsp","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]},{"type":"DRUG","name":"SGLT2 inhibitor","otherNames":[]}],"arms":[{"label":"iGlarLixi","type":"EXPERIMENTAL"},{"label":"IDegAsp","type":"ACTIVE_COMPARATOR"}],"summary":"This was a parallel-group treatment, Phase 3, randomized, 2-arm study that assessed the efficacy and safety of iGlarLixi to IDegAsp in Chinese T2DM participants insufficiently controlled with oral antidiabetic drug(s).\n\nStudy details included:\n\n* Study duration per participant: approximately up to 27 weeks\n* Treatment duration: 24 weeks\n* Visit frequency: after screening (an on-site visit), on-site or phone call visit every 1 week from randomization till Week 4, every 2 weeks till week 12 and then every 3 weeks till Week 24 (End of Treatment). There were 14 visits that included 7 phone calls and 7 on-site visits in total during screening and treatment periods. There was a safety follow-up by a phone call visit (End of Study) in 3 days after the last dose of the treatment.\n* Health measurement/Observation: change in HbA1c as the primary endpoint.\n* Intervention name: iGlarLixi and IDegAsp\n* Participant sex: male and female\n* Participant age range: adults at least 18 years of age\n* Condition/disease: Type 2 diabetes mellitus","primaryOutcome":{"measure":"Change in HbA1c From Baseline to Week 24: Non-Inferiority Analysis","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"iGlarLixi","deltaMin":-1.88,"sd":0.05},{"arm":"IDegAsp","deltaMin":-1.68,"sd":0.05}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":18},"locations":{"siteCount":60,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":290},"commonTop":["Upper Respiratory Tract Infection","Covid-19","Hyperuricaemia","Nausea","Lipase Increased"]}}